Pharm Exec22h
FDA Approves Roche’s Evrysdi for Spinal Muscular Atrophy
Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with ...
Monthly Prescribing Reference1d
Izervay Label Update Removes Limit on Treatment Duration for Geographic Atrophy
The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...
FOX News on MSN6d
Spinal cord stimulation restores movement for people with 'muscle wasting' disorder
New research suggests that electrical spinal cord stimulation could improve muscle function for patients who have spinal ...
Microsoft Study Details How The Overuse Of AI May Lead To Cognitive Atrophy
A study conducted by Microsoft shows the ways heavy reliance on AI can effect your cognitive ability in critical thinking.
Healio23h
Top in women’s health: Antidepressant use during pregnancy; prasterone lowers UTI risk
In a study of approximately 386,000 women published in JAMA Network Open, almost half of those who took antidepressants ...
BioSpace1d
Roche’s Evrysdi Becomes First Pill Cleared for Spinal Muscular Atrophy
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
The Associated Press on MSN9d
A spine-zapping implant helped 3 people with a muscle-wasting disease walk better
Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...
The American Journal of Managed Care1d
Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval
The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...
Managed Healthcare Executive17h
FDA Approves Expanded Label for Izervay, No Dosing Duration Limit
The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...